科学研究队伍

您现在的位置:首页 > 科研队伍 > 科学研究队伍

吕万良 教授

研究领域: 药剂学
电话: +86-10-82802683
联系邮箱: luwl@bjmu.edu.cn

个人简历

男,1966 年出生。北京大学教授、博士生导师、北京大学药学院党委副书记、药剂学系副主任、北京大学医学部纪委委员、北京大学医学部工会副主席。中国药学会药剂专业委员会副主任委员、中国颗粒学会常务理事;北京大学学报、中国新药杂志、中国药学杂志、BioMed Res. Int.等国内外学术期刊编委。从事肿瘤耐药性与药物递送系统生物药剂学研究。发表了研究论文150 余篇,部分论文发表于BiomaterialsJ. Control. ReleaseOncotarget 等药剂学科领域国际顶尖学术期刊上,近年获新药证书1 项、新药临床研究批件4 项;授权专利8 项;参编全国统编教材10 余部;获2009 年度教育部自然科学一等奖(第1 完成人)、2012 年度教育部自然科学一等奖(第2 完成人)等;培养的博士生获北京大学优秀博士论文奖6 项。

主要研究领域

1.肿瘤及其耐药靶标导向性载体药物传递系统的研究

2.药物新制剂研究

代表性论文

1. Zhang CX, Zhao WY, Liu L, Ju RJ, Mu LM, Zhao Y, Zeng F, Xie HJ, Yan Y, Lu WL*. A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment. Oncotarget. 2015;20;6(32):32681-700. (IF=6.359)

2. Zeng F, Ju RJ, Liu L, Xie HJ, Mu LM, Zhao Y, Yan Y, Hu YJ, Wu JS, Lu WL*. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer. Oncotarget 2015; 3;6(34):36625-42. (IF=6.359)

3. Shi JF, Sun MG, Li XY, Zhao Y, Ju RJ, Mu LM, Yan Y, Li XT, Zeng F, Lu WL*. A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer. J Biomed Nanotech. 2015;11(9): 1568-1582. (IF=5.338)

4. Sun MG, Shi JF, Li XY, Zhao Y. Ju RJ, Mu LM, Yan Y, Li XT, Zeng F, Lu WL*. Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer. J Biomed Nanotech. 2015;11(8): 1339–1353. (IF=5.338)

5. Zeng F, Ju RJ, Li XT, Lu WL*. Advances in investigations on the mechanism of cancer multidrug resistance and the liposomes-based treatment strategy. Journal of Pharmaceutical Investigation. December 2014 Dec; 44(7): 493-504.

6. Ju RJ, Li XT, Shi JF, Li XY, Sun MG, Zeng F, Zhou J, Liu L, Zhang CX, Zhao WY, Lu WL*. Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials. 2014 Aug;35(26):7610-21. (IF=8.557)

7. Li XY, Zhao Y, Sun MG, Shi JF, Ju RJ, Zhang CX, Li XT, Zhao WY, Mu LM, Zeng F, Lou JN, Lu WL*. Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. Biomaterials. 2014 Jul;35(21):5591-604. (IF=8.557)

8. Li XT, Ju RJ, Li XY, Zeng F, Shi JF, Liu L, Zhang CX, Sun MG, Lou JN, Lu WL*. Multifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cells. Oncotarget. 2014 Aug 15;5(15):6497-511. (IF=6.359)

9. Ju RJ, Mu LM, Lu WL*. Research Spotlight: Targeting drug delivery systems for circumventing multidrug resistance of cancers. Ther Deliv. 2013 Jun;4(6):667-71

10. Ma X, Zhou J, Zhang CX, Li XY, Li N, Ju RJ, Shi JF, Sun MG, Zhao WY, Mu LM, Yan Y, Lu WL*. Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. Biomaterials. 2013 Jun;34(18):4452-65. (IF=8.312)

11. Zhou J, Zhao WY, Ma X, Ju RJ, Li XY, Li N, Sun MG, Shi JF, Zhang CX, Lu WL*.The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials. 2013 May;34(14):3626-38. (IF=8.312)

12. Li N, Zhang CX, Wang XX, Zhang L, Ma X, Zhou J, Ju RJ, Li XY, Zhao WY, Lu WL*. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways. Biomaterials. 2013 Apr;34(13):3366-80. (IF=8.312)

13. Li Y, He H, Jia X*, Lu WL*, Lou J, Wei Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials. 2012 May;33(15):3899-908. (IF=7.604)

14. Yu Y, Wang ZH, Zhang L, Yao HJ, Zhang Y, Li RJ, Ju RJ, Wang XX, Zhou J, Li N, Lu WL*. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. Biomaterials. 2012 Feb; 33(6):1808-20. (IF=7.604)

15. Zhang L, Yao HJ, Yu Y, Zhang Y, Li RJ, Ju RJ, Wang XX, Sun MG, Shi JF, Lu WL*. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials. 2012 Jan;33(2):565-82. (7.604)

16. Ju RJ, Huang RJ, Zhou J, Li RJ, Zhou P, Zhang ZH, Xiang FJ, Xu DJ, Liu WX, Ma XT, Zhang Q, Lu WL*. Separation of injectable salidroside by column chromatography of macroporous resins for treating myocardial ischemia. Science China Chemistry, 2012, 55(7): 1435–1444. (IF=1.327)

17. Men Y, Wang XX, Li RJ, Zhang Y, Tian W, Yao HJ, Ju RJ, Ying X, Zhou J, Li N, Zhang L, Yu Y, Lu WL*. The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals. Int J Nanomedicine. 2011;6:3125-37. (IF=3.130)

18. Wang XX, Li YB, Yao HJ, Ju RJ, Zhang Y, Li RJ, Yu Y, Zhang L, Lu WL*. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials. 2011 Aug;32(24):5673-87. (IF=7.404)

19. Yao HJ, Ju RJ, Wang XX, Zhang Y, Li RJ, Yu Y, Zhang L, Lu WL*. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials. 2011 Feb; 32:3285-3302. (IF=7.404)

20. Ying X, Wen H, Yao HJ, Zhang Y, Tian W, Zhang L, Ju RJ, Wang XX, Yu Y, Lu WL*. Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice. Pharmacology. 2011 Feb 1;87(1-2):105-114. (IF=1.788)

21. Zhang Y, Ying X, Tian W, Li RJ, Yao HJ, Men Y, Yu Y, Zhang L, Ju RJ, Wang XX, Zhou J, Chen JX, Li N, Lu WL*. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer. Mol Pharm. 2011 Feb 7;8(1):162-75. (IF=4.782)

22. Li RJ, Ying X, Zhang Y, Ju RJ, Wang XX, Yao HJ, Men Y, Tian W, Yu Y, Zhang L, Huang RJ, Lu WL*. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J Control Release. 2011 Feb , 149(3):281-291. (IF=6.499)

科研项目